Clinicians and patients may have an injectable form of the immunotherapy nivolumab (Opdivo, Bristol Myers Squibb) available in their future. A phase 3 study, CheckMate-67T, has shown that subcutaneous injection of nivolumab is noninferior to IV delivery and dramatically reduces treatment time in patients with renal cell carcinoma (RCC). The study findings were reported at the 2024 ASCO Genitourinary Cancers Symposium (abstract LBA360).
Because nivolumab is FDA approved for more than 20
MARCH 29, 2024